Full name :
First name :
Mail :
Zip Code :
City :
Country :
Email :
Phone :
Fax :
Website :
Directory :
| Title : Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats - Retlich_2009_Biopharm.Drug.Dispos_30_422 |
| Author(s) : Retlich S , Withopf B , Greischel A , Staab A , Jaehde U , Fuchs H |
| Ref : Biopharmaceutics & Drug Disposition , 30 :422 , 2009 |
| Abstract : Retlich_2009_Biopharm.Drug.Dispos_30_422 |
| ESTHER : Retlich_2009_Biopharm.Drug.Dispos_30_422 |
| PubMedSearch : Retlich_2009_Biopharm.Drug.Dispos_30_422 |
| PubMedID: 19771584 |
| Title : Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans - Fuchs_2009_J.Pharm.Pharmacol_61_55 |
| Author(s) : Fuchs H , Tillement JP , Urien S , Greischel A , Roth W |
| Ref : J Pharm Pharmacol , 61 :55 , 2009 |
| Abstract : Fuchs_2009_J.Pharm.Pharmacol_61_55 |
| ESTHER : Fuchs_2009_J.Pharm.Pharmacol_61_55 |
| PubMedSearch : Fuchs_2009_J.Pharm.Pharmacol_61_55 |
| PubMedID: 19126297 |
| Title : 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes - Eckhardt_2007_J.Med.Chem_50_6450 |
| Author(s) : Eckhardt M , Langkopf E , Mark M , Tadayyon M , Thomas L , Nar H , Pfrengle W , Guth B , Lotz R , Sieger P , Fuchs H , Himmelsbach F |
| Ref : Journal of Medicinal Chemistry , 50 :6450 , 2007 |
| Abstract : Eckhardt_2007_J.Med.Chem_50_6450 |
| ESTHER : Eckhardt_2007_J.Med.Chem_50_6450 |
| PubMedSearch : Eckhardt_2007_J.Med.Chem_50_6450 |
| PubMedID: 18052023 |
| Gene_locus related to this paper: human-DPP4 |